Next Article in Journal
Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study
Next Article in Special Issue
STAT3 Activation and Oncogenesis in Lymphoma
Previous Article in Journal
The Genetic Architecture of Gliomagenesis–Genetic Risk Variants Linked to Specific Molecular Subtypes
Previous Article in Special Issue
Deleterious and Oncogenic Mutations in the IL7RA
Review

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

1
Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, VIC, Melbourne 3000, Australia
2
Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Parkville 3052, Australia
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(12), 2002; https://doi.org/10.3390/cancers11122002
Received: 14 November 2019 / Revised: 6 December 2019 / Accepted: 9 December 2019 / Published: 12 December 2019
(This article belongs to the Special Issue JAK-STAT Signalling Pathway in Cancer)
Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape. Antitumor immune responses are largely driven by STAT1 and STAT2 induction of type I and II interferons (IFNs) and the downstream programs IFNs potentiate. Conversely, STAT3 has been widely linked to cancer cell survival, immunosuppression, and sustained inflammation in the tumor microenvironment. The discovery of JAK-STAT cross-regulatory mechanisms, post-translational control, and non-canonical signal transduction has added a new level of complexity to JAK-STAT governance over tumor initiation and progression. Endeavors to better understand the vast effects of JAK-STAT signaling on antitumor immunity have unearthed a wide range of targets, including oncogenes, miRNAs, and other co-regulatory factors, which direct specific phenotypical outcomes subsequent to JAK-STAT stimulation. Yet, the rapidly expanding field of therapeutic developments aimed to resolve JAK-STAT aberrations commonly reported in a multitude of cancers has been marred by off-target effects. Here, we discuss JAK-STAT biology in the context of immunity and cancer, the consequences of pathway perturbations and current therapeutic interventions, to provide insight and consideration for future targeting innovations. View Full-Text
Keywords: JAK; STAT; signaling; interferons; immunosurveillance; inflammation; cancer JAK; STAT; signaling; interferons; immunosurveillance; inflammation; cancer
Show Figures

Figure 1

MDPI and ACS Style

Owen, K.L.; Brockwell, N.K.; Parker, B.S. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers 2019, 11, 2002. https://doi.org/10.3390/cancers11122002

AMA Style

Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers. 2019; 11(12):2002. https://doi.org/10.3390/cancers11122002

Chicago/Turabian Style

Owen, Katie L., Natasha K. Brockwell, and Belinda S. Parker 2019. "JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression" Cancers 11, no. 12: 2002. https://doi.org/10.3390/cancers11122002

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop